Xbrane Biopharma announces that Carlo Colombo, Head of Production within Xbranes long acting injectable business, who forms a part of Xbranes management team, has on own initiative resigned.
Carlo Colombo joined Xbrane Biopharma in January 2016 and has since then headed the commercial production of Spherotide.
“It is with a heavy heart we see Carlo Colombo leave the company. Carlo’s contribution to the company has been very significant, particularly in the process of achieving GMP certification of our production facility and ramping up commercial production of Spherotide. On behalf of all Xbrane employees and the Board of Directors I want to thank Carlo for his contributions and wish him all the best in his new position,” said Martin Åmark, CEO.
Xbrane has initiated the process to recruit a successor to Carlo, and in the interim period Paolo Sarmientos, Head of long acting injectables at Xbrane, will assume his position. The change in management will not impact the production and sale of Spherotide.
The resignation will take effect from 28 February 2018.
